Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 5 |
| List of Tables | 5 | 1 |
| List of Figures | 6 | 1 |
| Introduction | 7 | 1 |
| Global Markets Direct Report Coverage | 7 | 1 |
| Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) Overview | 8 | 1 |
| Therapeutics Development | 9 | 4 |
| Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) Products under Development by Stage of Development | 9 | 1 |
| Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) Products under Development by Therapy Area | 10 | 1 |
| Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) Products under Development by Indication | 11 | 2 |
| Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) Pipeline Products Glance | 13 | 2 |
| Late Stage Products | 13 | 1 |
| Early Stage Products | 14 | 1 |
| Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) Products under Development by Companies | 15 | 5 |
| Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) Products under Development by Universities/Institutes | 20 | 2 |
| Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) Therapeutics Assessment | 22 | 6 |
| Assessment by Monotherapy/Combination Products | 22 | 1 |
| Assessment by Mechanism of Action | 23 | 1 |
| Assessment by Route of Administration | 24 | 2 |
| Assessment by Molecule Type | 26 | 2 |
| Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) Companies Involved in Therapeutics Development | 28 | 10 |
| Beta Pharma, Inc. | 28 | 1 |
| Eli Lilly and Company | 29 | 1 |
| G1 Therapeutics, Inc. | 30 | 1 |
| Jiangsu Hengrui Medicine Co., Ltd. | 31 | 1 |
| Novartis AG | 32 | 1 |
| Onconova Therapeutics, Inc. | 33 | 1 |
| Pfizer Inc. | 34 | 1 |
| Sihuan Pharmaceutical Holdings Group Ltd. | 35 | 1 |
| Teijin Pharma Limited | 36 | 1 |
| ViroStatics srl | 37 | 1 |
| Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) Drug Profiles | 38 | 36 |
| abemaciclib Drug Profile | 38 | 5 |
| BPI-1178 Drug Profile | 43 | 1 |
| FLX-925 Drug Profile | 44 | 1 |
| G-1T28 Drug Profile | 45 | 2 |
| G-1T38 Drug Profile | 47 | 1 |
| GZ-381 Drug Profile | 48 | 1 |
| MMD-37K Drug Profile | 49 | 1 |
| ON-123300 Drug Profile | 50 | 1 |
| palbociclib Drug Profile | 51 | 10 |
| ribociclib succinate Drug Profile | 61 | 4 |
| SHR-6390 Drug Profile | 65 | 1 |
| Small Molecule to Inhibit CDK 4 and 6 for Rheumatoid Arthritis Drug Profile | 66 | 1 |
| Small Molecule to Inhibit CDK4 and CDK6 for Acute Kidney Injury and Breast Cancer Drug Profile | 67 | 1 |
| Small Molecule to Inhibit CDK4 and CDK6 for Breast Cancer Drug Profile | 68 | 1 |
| Small Molecule to Inhibit CDK4, CDK6 and CDK9 for HPV Associated Cancers Drug Profile | 69 | 1 |
| Small Molecule to Inhibit CDK4, CDK6 and CDK9 for HSV Infections Drug Profile | 70 | 1 |
| Small Molecule to Inhibit CDK4, CDK6 and CDK9 for Oncology Drug Profile | 71 | 1 |
| Small Molecules to Inhibit CDK4, CDK6 and CDK9 for EBV Infections Drug Profile | 72 | 1 |
| Small Molecules to Inhibit Cyclin D1, CDK6, EGFR and VEGF for Oncology Drug Profile | 73 | 1 |
| Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) Dormant Projects | 74 | 1 |
| Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) Discontinued Products | 75 | 1 |
| Cyclin-Dependent Kinase 6 (Cell Division Protein Kinase 6 or EC 2.7.11.22) Featured News &Press Releases | 76 | 15 |
| Jun 03, 2016: Lilly Announces Results From MONARCH 1 Trial Of Abemaciclib Monotherapy | 76 | 1 |
| May 31, 2016: Lilly Announces Webcast To Discuss Abemaciclib Data | 77 | 1 |
| May 23, 2016: Investigational CDK4/6 inhibitor abemaciclib is active against a range of cancer types | 77 | 1 |
| May 18, 2016: Eli Lilly to Present final phase 2 monotherapy data on CDK 4 and 6 inhibitor abemaciclib in metastatic breast cancer at ASCO | 78 | 1 |
| May 18, 2016: MONALEESA-2 trial of Novartis' LEE011 (ribociclib) stopped due to positive efficacy results at interim analysis in HR+/HER2- advanced breast cancer | 79 | 1 |
| May 10, 2016: Health Canada approves new first-line treatment for women living with metastatic breast cancer | 80 | 1 |
| Apr 20, 2016: Onconova Announces Novel Dual Targeting of ARK5 and CDK4/6 by Pre-clinical Compound, ON 123300, in Presentation at 2016 American Association of Cancer Research (AACR) Annual Meeting | 81 | 1 |
| Apr 19, 2016: Pfizer Announces Positive Top-Line Results For Phase 3 PALOMA-2 Clinical Trial Of IBRANCE (Palbociclib) | 82 | 1 |
| Apr 15, 2016: G1 Therapeutics to Present Preliminary clinical data on CDK4/6 Inhibitor G1T28 at the 2016 American Association for Cancer Research Annual Meeting | 83 | 1 |
| Apr 15, 2016: G1 Therapeutics to Present Preclinical Data on CDK4/6 Inhibitor G1T38 at the 2016 American Association for Cancer Research Annual Meeting | 84 | 1 |
| Mar 14, 2016: New agent overcomes drug resistance in HER2-positive breast cancer preclinical study shows | 84 | 2 |
| Mar 07, 2016: New therapeutic target in myeloma discovered | 86 | 1 |
| Mar 02, 2016: Drug combination slows breast cancer spread | 87 | 1 |
| Feb 19, 2016: Pfizer Receives Expanded FDA Approval For IBRANCE (palbociclib) In HR+, HER2- Metastatic Breast Cancer | 88 | 2 |
| Dec 29, 2015: New breast cancer drug may be effective against other types of cancer | 90 | 1 |
| Appendix | 91 | 2 |
| Methodology | 91 | 1 |
| Coverage | 91 | 1 |
| Secondary Research | 91 | 1 |
| Primary Research | 91 | 1 |
| Expert Panel Validation | 91 | 1 |
| Contact Us | 91 | 1 |
| Disclaimer | 92 | 1 |